Literature DB >> 19123007

Polycystic ovary syndrome and fibrocystic breast disease: is there any association?

Ilknur Inegol Gumus1, Asli Koktener, Dilek Dogan, Nilgun Ozturk Turhan.   

Abstract

OBJECTIVE: We aimed to investigate the association between a polycystic ovary syndrome (PCOS) and fibrocystic breast disease.
METHODS: A total of 93 women, aged between 17 and 36 years, not using oral contraceptives, were entered in this case-control study. Laboratory, clinical and ultrasound findings were used to diagnose PCOS. The study group was consisted of 53 PCOS women and the control group consisted of 40 women. Breast ultrasonography was performed for all patients. Fibrocystic breast disease is described as common benign changes involving the tissues of the breast.
RESULTS: Twenty-one (39.6%) of 53 women with a PCOS had fibrocystic breast disease. Five (8%) of 40 controls had fibrocystic breast disease. The difference between the groups was statistically significant (p = 0.004). Relative risk (95% CIs) was 3.17 (1.31-7.68). Overall sonographic benign breast pathologies were significantly higher in the PCOS group (p = 0.036).
CONCLUSION: This study showed a statistically significant association between a PCOS and fibrocystic breast disease. Women with a PCOS should be evaluated for fibrocystic breast disease.

Entities:  

Mesh:

Year:  2009        PMID: 19123007     DOI: 10.1007/s00404-008-0889-8

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  2 in total

1.  Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial.

Authors:  Sadaf Alipour; Hadith Rastad; Azin Saberi; Firoozeh Faiz; Arezoo Maleki-Hajiagha; Mahboubeh Abedi
Journal:  Daru       Date:  2021-10-31       Impact factor: 3.117

Review 2.  The effect of the polycystic ovary syndrome and hypothyroidism on the risk of fibrocystic breast changes: a meta-analysis.

Authors:  Parisa Kohnepoushi; Hojat Dehghanbanadaki; Pardis Mohammadzedeh; Maziar Nikouei; Yousef Moradi
Journal:  Cancer Cell Int       Date:  2022-03-19       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.